source
- Neumora ends development of navacaprant after failed Phase 3 depression trials; EnGene cuts half its workforceNeumora Therapeutics announced it will discontinue its kappa opioid receptor antagonist navacaprant after the drug missed its primary endpoints in two Phase 3 studies for major depressive disorder.…
- Eli Lilly to acquire non-opioid pain drug developer 4E Therapeutics, adding MNK inhibitor pipelineEli Lilly announced it will purchase 4E Therapeutics, a biotech focused on non‑opioid pain treatments. The acquisition gives Lilly access to 4E’s experimental pipeline, including MNK inhibitors su…